Unknown

Dataset Information

0

Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate.


ABSTRACT: Plasminogen activator inhibitor type-1 (PAI-1) is a serine protease inhibitor (serpin) implicated in numerous pathological processes, including coronary heart disease, arterial and venous thrombosis, and chronic fibrotic diseases. These associations have made PAI-1 an attractive pharmaceutical target. However, the complexity of the serpin inhibitory mechanism, the inherent metastability of serpins, and the high-affinity association of PAI-1 with vitronectin in vivo have made it difficult to identify pharmacologically effective small-molecule inhibitors. Moreover, the majority of current small-molecule PAI-1 inhibitors are poor pharmaceutical candidates. To this end and to find leads that can be efficiently applied to in vivo settings, we developed a dual-reporter high-throughput screen (HTS) that reduced the rate of nonspecific and promiscuous hits and identified leads that inhibit human PAI-1 in the high-protein environments present in vivo Using this system, we screened >152,000 pure compounds and 27,000 natural product extracts (NPEs), reducing the apparent hit rate by almost 10-fold compared with previous screening approaches. Furthermore, screening in a high-protein environment permitted the identification of compounds that retained activity in both ex vivo plasma and in vivo Following lead identification, subsequent medicinal chemistry and structure-activity relationship (SAR) studies identified a lead clinical candidate, MDI-2268, having excellent pharmacokinetics, potent activity against vitronectin-bound PAI-1 in vivo, and efficacy in a murine model of venous thrombosis. This rigorous HTS approach eliminates promiscuous candidate leads, significantly accelerates the process of identifying PAI-1 inhibitors that can be rapidly deployed in vivo, and has enabled identification of a potent lead compound.

SUBMITTER: Reinke AA 

PROVIDER: S-EPMC6364767 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dual-reporter high-throughput screen for small-molecule <i>in vivo</i> inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate.

Reinke Ashley A AA   Li Shih-Hon SH   Warnock Mark M   Shaydakov Maxim E ME   Guntaka Naga Sandhya NS   Su Enming J EJ   Diaz Jose A JA   Emal Cory D CD   Lawrence Daniel A DA  

The Journal of biological chemistry 20181203 5


Plasminogen activator inhibitor type-1 (PAI-1) is a <u>ser</u>ine <u>p</u>rotease <u>in</u>hibitor (serpin) implicated in numerous pathological processes, including coronary heart disease, arterial and venous thrombosis, and chronic fibrotic diseases. These associations have made PAI-1 an attractive pharmaceutical target. However, the complexity of the serpin inhibitory mechanism, the inherent metastability of serpins, and the high-affinity association of PAI-1 with vitronectin <i>in vivo</i> ha  ...[more]

Similar Datasets

| S-EPMC2854128 | biostudies-literature
| S-EPMC3909729 | biostudies-literature
| S-EPMC7696990 | biostudies-literature
| S-EPMC5428408 | biostudies-literature
| S-EPMC4047425 | biostudies-literature
| S-EPMC3044959 | biostudies-literature
| S-EPMC7810990 | biostudies-literature
| S-EPMC4514594 | biostudies-literature
| S-EPMC10663445 | biostudies-literature
| S-EPMC4801272 | biostudies-literature